Endostatin: A Promising Biomarker in the Cardiovascular Continuum?

Abstract

The current review article aims to provide an up-to-date summary of previous studies in humans that have reported the association between circulating endostatin levels and different cardiovascular phenotypes. We also aim to provide suggestions for future directions of future research evaluating endostatin as a clinically relevant cardiovascular biomarker. With a few exceptions, higher circulating levels of endostatin seem to reflect vascular and myocardial damage, and a worsened prognosis for cardiovascular events or mortality in individuals with hypertension, diabetes, kidney disease, cardiovascular disease, as well as in the general population. Circulating endostatin seems to be a promising biomarker for cardiovascular pathology, but there is not enough evidence to date to support the use of endostatin measurements in clinical practice.

Keywords: :

• angiogenesis
• atherosclerosis
• biomarker
• chronic kidney disease
• collagen XVIII
• epidemiological studies
• extracellular matrix
• glomerular filtration rate
• heart failure
• mortality

Financial & competing interests disclosure

This study was supported by The Swedish Research Council, Swedish Heart-Lung foundation, the European Union Horizon 2020 (grant number 634869), the Marianne and Marcus Wallenberg Foundation, Dalarna University and Uppsala University. The funding sources had no input on the study design, analysis or manuscript preparation. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Additional information

Funding

This study was supported by The Swedish Research Council, Swedish Heart-Lung foundation, the European Union Horizon 2020 (grant number 634869), the Marianne and Marcus Wallenberg Foundation, Dalarna University and Uppsala University. The funding sources had no input on the study design, analysis or manuscript preparation. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.